FR2478470A1 - Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications - Google Patents
Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications Download PDFInfo
- Publication number
- FR2478470A1 FR2478470A1 FR8006537A FR8006537A FR2478470A1 FR 2478470 A1 FR2478470 A1 FR 2478470A1 FR 8006537 A FR8006537 A FR 8006537A FR 8006537 A FR8006537 A FR 8006537A FR 2478470 A1 FR2478470 A1 FR 2478470A1
- Authority
- FR
- France
- Prior art keywords
- cells
- sep
- glutaraldehyde
- substance
- toxic substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 15
- 244000005700 microbiome Species 0.000 title claims abstract description 9
- 239000011149 active material Substances 0.000 title abstract 4
- 239000000677 immunologic agent Substances 0.000 title 1
- 229940124541 immunological agent Drugs 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 117
- 238000002360 preparation method Methods 0.000 claims abstract description 57
- 239000003440 toxic substance Substances 0.000 claims abstract description 50
- 239000000126 substance Substances 0.000 claims abstract description 34
- 239000003053 toxin Substances 0.000 claims abstract description 15
- 231100000765 toxin Toxicity 0.000 claims abstract description 15
- 108700012359 toxins Proteins 0.000 claims abstract description 15
- 230000001413 cellular effect Effects 0.000 claims abstract description 11
- 231100000614 poison Toxicity 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 6
- 231100000331 toxic Toxicity 0.000 claims abstract description 6
- 230000002588 toxic effect Effects 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 5
- 239000000470 constituent Substances 0.000 claims abstract description 5
- 231100000611 venom Toxicity 0.000 claims abstract description 5
- 239000005556 hormone Substances 0.000 claims abstract description 4
- 229940088597 hormone Drugs 0.000 claims abstract description 4
- 230000001580 bacterial effect Effects 0.000 claims abstract description 3
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 3
- 244000045947 parasite Species 0.000 claims abstract description 3
- 239000002435 venom Substances 0.000 claims abstract description 3
- 210000001048 venom Anatomy 0.000 claims abstract description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 56
- 231100000167 toxic agent Toxicity 0.000 claims description 41
- 229960005486 vaccine Drugs 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- 230000002779 inactivation Effects 0.000 claims description 12
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- 229940118376 tetanus toxin Drugs 0.000 claims description 10
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 9
- 230000000144 pharmacologic effect Effects 0.000 claims description 9
- 238000001784 detoxification Methods 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 239000012429 reaction media Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 3
- 239000011541 reaction mixture Substances 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims description 2
- 238000009109 curative therapy Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000000521 hyperimmunizing effect Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract description 2
- 230000003328 fibroblastic effect Effects 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 108010062580 Concanavalin A Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001147 anti-toxic effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960002766 tetanus vaccines Drugs 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000002096 anti-tetanic effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000003948 anatoxin Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960004279 formaldehyde Drugs 0.000 description 2
- -1 haptens Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000012985 polymerization agent Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000526 Experimental Leukemia Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000711 cavernous sinus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8006537A FR2478470A1 (fr) | 1980-03-24 | 1980-03-24 | Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications |
| FR8113524A FR2487201B2 (fr) | 1980-03-24 | 1981-07-09 | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8006537A FR2478470A1 (fr) | 1980-03-24 | 1980-03-24 | Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2478470A1 true FR2478470A1 (fr) | 1981-09-25 |
| FR2478470B1 FR2478470B1 (enExample) | 1983-08-05 |
Family
ID=9240025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8006537A Granted FR2478470A1 (fr) | 1980-03-24 | 1980-03-24 | Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2478470A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2577048A1 (fr) * | 1985-02-05 | 1986-08-08 | Pasteur Institut | Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application |
| WO1986005398A1 (fr) * | 1985-03-18 | 1986-09-25 | Pascal Berdal | Preparations pharmaceutiques immunomodulantes |
-
1980
- 1980-03-24 FR FR8006537A patent/FR2478470A1/fr active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2577048A1 (fr) * | 1985-02-05 | 1986-08-08 | Pasteur Institut | Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application |
| EP0193439A1 (fr) * | 1985-02-05 | 1986-09-03 | Institut Pasteur | Réactif pour le dosage par hémagglutination des anticorps contre les toxines bactériennes, procédé de préparation et son application |
| US5318913A (en) * | 1985-02-05 | 1994-06-07 | Edgar H. Relyveld | Reagent for the determination by hemagglutination of antibodies to bacterial toxins, method of preparation and application thereof |
| WO1986005398A1 (fr) * | 1985-03-18 | 1986-09-25 | Pascal Berdal | Preparations pharmaceutiques immunomodulantes |
| FR2587217A1 (fr) * | 1985-03-18 | 1987-03-20 | Berdal Pascal | Preparations pharmaceutiques immunomodulantes |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2478470B1 (enExample) | 1983-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0828511B1 (fr) | Composition vaccinale anti-Haemophilus influenzae de type b comprenant du polyribosylribitol phosphate et son procédé de préparation | |
| WO1998051339A1 (fr) | Composition vaccinale multivalente a porteur mixte | |
| FR2468372A1 (fr) | Nouveau vaccin contre les maladies infectieuses chez les bovins et son procede de production | |
| FR2859633A1 (fr) | Immunogene synthetique pour le traitement et la prevention des abus de produits narcotiques et psychoactifs | |
| EP0814834B1 (fr) | Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps diriges contre ces immunogenes, procede pour leur preparation et compositions pharmaceutiques les renfermant | |
| EP1446422B1 (fr) | Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine (hbha) methylee | |
| FR2806304A1 (fr) | Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie | |
| BE1021938B1 (fr) | Composition immunogene pour une utilisation en therapie | |
| FR2460139A1 (fr) | Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction | |
| EP0001197A2 (fr) | Produits de couplage de la cytidine-diphosphocholine et de composés aminés, procédé d'obtention et application pharmaceutique et analytique | |
| FR2590172A1 (fr) | Nouvel antigene commun (psc-a) de pseudomonas aeruginosa protegeant contre l'infection provoquee par cet organisme | |
| WO1989005631A1 (fr) | Compositions presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire | |
| FR2478470A1 (fr) | Preparations cellulaires applicables en therapeutique humaine, procede d'obtention et applications | |
| FR2522269A1 (fr) | Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux | |
| EP0468049A1 (fr) | Anticorps monoclonaux reconnaissant un peptide associe a un antigene majeur d'histocompatibilite | |
| FR2487201A2 (fr) | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications | |
| FR2577048A1 (fr) | Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application | |
| EP0799053A1 (fr) | Vaccin presentant une immunogenicite accrue | |
| CH650932A5 (en) | Cell preparations which can be used in human therapy and method for obtaining them | |
| WO2016185135A1 (fr) | Traitement et detection des trypanosomoses | |
| DK144528B (da) | Fremgangsmaade til fremstilling af et derivat af fragment b af difteritoxin | |
| FR2736064A1 (fr) | Epitopes protecteurs de l'adenyl cyclase-hemolysine(ac-hty). leur application au traitement ou a la prevention des infections par bordetella | |
| WO1983003354A1 (en) | Neisseria gonorrhoeae vaccine | |
| FR2479000A1 (fr) | Vaccin contre la brucellose, maladie du betail | |
| BE1001844A4 (fr) | Anticorps monoclonal humain contre pseudomonas aeruginosa, sa production et son application. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| CL | Concession to grant licences |